Samrat Pharmachem Ltd

Samrat Pharmachem Board Meeting Date

Samrat Pharmachem will hold a board meeting on November 14, 2026, to consider its unaudited quarterly financial results for the period ended September 2026.

Samrat Pharmachem Other Announcement

Samrat Pharmachem Limited appointed M/s Divyesh J Shah & Associates as Statutory Auditors following the expiry of the previous auditor's tenure at the 34th Annual General Meeting.

Samrat Pharmachem Annual General Meeting

Samrat Pharmachem Limited held its 34th Annual General Meeting on September 23, 2026. The meeting successfully transacted the business items outlined in the prior meeting notice.

Samrat Pharmachem Annual General Meeting

Samrat Pharmachem will hold its 34th Annual General Meeting on September 23, 2026, via video conferencing. The company also announced book closure dates for shareholders.

Samrat Pharmachem Annual Report

Samrat Pharmachem filed its 34th Annual Report for FY 2025-26. The company's 34th AGM is scheduled for September 23, 2026, via video conferencing.

Samrat Pharmachem Q1 FY27 Results: Turns Profitable, Net Profit ₹0.9 Cr

Samrat Pharmachem Ltd reported revenue from operations of ₹79.8 Cr (+5.4% YoY) and net profit of ₹0.9 Cr for Q1 FY27.

Key figure

Net profit ₹0.9 Cr

Samrat Pharmachem Business Update

Samrat Pharmachem Ltd issued a duplicate share certificate to one shareholder. The issuance replaces 400 original shares that were lost.

Samrat Pharmachem Other Announcement

Samrat Pharmachem appointed Divyesh J Shah & Associates as Statutory Auditors for five years. The term spans from the 34th to 39th Annual General Meeting.

Execution

5 years

Samrat Pharmachem Board Meeting Date

Samrat Pharmachem Ltd issued notice of a board meeting on 14 Aug 2026 to approve its unaudited QJune‑2026 results. The meeting will be held at its Mumbai office.

Samrat Pharmachem Q4 FY26 Results: Net Loss of ₹2 Cr, Loss Widens

Samrat Pharmachem Ltd reported revenue from operations of ₹71.8 Cr (+0.8% YoY) and a net loss of ₹2 Cr for Q4 FY26.

Key figure

Net loss ₹2 Cr

Samrat Pharmachem Financial Results

Samrat Pharmachem reported an annual total income of ₹290.55 Crore for FY26. The board also fixed the 34th AGM date for September 23, 2026.

Value

₹290.6 Cr

Samrat Pharmachem Other Announcement

Samrat Pharmachem Limited submitted its Annual Secretarial Compliance Report for FY 2025-26. The report by A.A. Mulla & Associates confirms general regulatory adherence with minor historical filing delays.

Samrat Pharmachem Debt & Borrowing

Samrat Pharmachem Limited filed its initial disclosure under the SEBI Large Corporate framework for the financial year. The company confirmed it does not meet the criteria to be identified as a Large Corporate, reporting zero outstanding borrowings as of March 31.

Samrat Pharmachem Other Announcement

Samrat Pharmachem Limited submitted a compliance certificate under Regulation 74(5) for the quarter ended March 31, 2026. The Registrar and Share Transfer Agent, MUFG Intime India, confirmed that securities received for dematerialisation were processed and listed on the stock exchange within prescribed timelines.

Samrat Pharmachem Q3 FY26 Results: Net Loss of ₹0.5 Cr

Samrat Pharmachem Ltd reported a net loss of ₹0.5 Cr for Q3 FY26.

Key figure

Net loss ₹0.5 Cr